Full Text
EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada

Abstract

Authors

A. Fischer S. Mac E. Freiman J. Marshall K. Rand J.M. Ramos-Goni

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×